Search is Powered by Google
Tuberculosis News

Extensively Drug-resistant Tuberculosis (XDR-TB): The Value Of A Clear Definition

Main Category: Tuberculosis
Also Included In: Infectious Diseases / Bacteria / Viruses
Article Date: 28 Sep 2007 - 18:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:4 and a half stars

4.5 (2 votes)

Health Professional:5 stars

5 (1 votes)

Article Opinions: 0 posts

Extensively drug resistant tuberculosis (XDR-TB) represents a spectre for the civil society and a major challenge for the TB control community.

The ERS has played a key role in fighting XDR-TB, promoting important studies and publishing some of them in the European Respiratory Journal, the scientific publication of the ERS. In addition, some relevant studies on XDR-TB have been developed by TBNET (TuBerculosis Network in Europe Trials group), a network of research centres operating within the ERS study group "Tuberculosis".

In this issue, the TBNET study reports on 4,583 confirmed TB cases in Italy, Germany, Estonia and Russia (Archangels Oblast).

Treatment outcomes of 64 XDR (1) cases, 267 multidrug-resistant (MDR) (2) cases resistant to all first-line drugs, and of 94 "other" MDR cases (susceptible, at least, to one first-line anti-TB drug) are compared.

The results of the study demonstrate that XDR cases have a worse outcome (death or failure, i.e. treatment fails to render the patient non-infectious) than MDR cases resistant to all first-line drugs, and of "other" MDR cases (susceptible, at least, to one first-line anti-TB drug).
The study also demonstrates that the XDR definition proposed by WHO has both a clinical (predicts poor outcome), and operational value (confirming these cases are resistant to both first-line drugs and key second-line ones).

(1) XDR: cases resistant at least to isoniazid and rifampicin, plus at least one fluoroquinolone (new generation second-line drug) and one injectable second-line drug
(2) MDR: cases resistant to at least isoniazid and rifampicin, the two most powerful anti-TB drugs

The European Respiratory Journal is the peer-reviewed scientific publication of the European Respiratory Society (more than 8,000 specialists in lung diseases and respiratory medicine in Europe, the United States and Australia).

European Respiratory Society




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
TB Patient Gets New Windpipe Made With Own Stem Cells
19 Nov 2008
A 30-year old Columbian woman living in Spain whose airway was damaged from tuberculosis is the first person in the world to receive a new airway engineered from tissue that was grown from her own stem cells which means she...


Involving Your Kids in Their Nutrition
Involving Your Kids in Their Nutrition

Nutrition experts recommend getting your kids involved in their nutrition decisions, and making sure they understand why good nutrition is important.

more videos are available in our health videos section.